SCHEMBL24596243

SCHEMBL24596243

Cc1c(F)cccc1Nc1nc(C(F)(F)F)ccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
OPRM1 P35372 1/20 0.37
DHODH Q02127 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
TGFBR1 P36897 2/20 0.35
ULK1 O75385 1/20 0.34
SYK P43405 2/20 0.33
TAS2R14 Q9NYV8 1/20 0.33
GALR2 O43603 1/20 0.33
GALR1 P47211 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
P2RX7 Q99572 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HDAC4 P56524 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596390 0.86 LMNA (0.45) LMNAHDAC6TAS2R14SMN1; SMN2HDAC4
SCHEMBL24596360 0.84 LMNA (0.36) LMNATGFBR1ULK1SYKTAS2R14
SCHEMBL24596326 0.83 TYK2 (0.46) LMNATGFBR1ULK1SYK
SCHEMBL24596182 0.82 CCR4 (0.40) LMNAHDAC6SMN1; SMN2HDAC4
SCHEMBL30283182 0.81 LMNA (0.39) LMNAOPRM1SYKGALR2GALR1
SCHEMBL24596254 0.80 ENPP3 (0.35) LMNATGFBR1SYKTAS2R14RXRA
SCHEMBL24596302 0.78 MAT2A (0.39) LMNADHODHHDAC6SYKTAS2R14
SCHEMBL24596297 0.77 EPHX2 (0.47) LMNAULK1TAS2R14ALDH1A1GAA
SCHEMBL24596400 0.77 IGF1R (0.42) LMNADHODHTGFBR1SYKTAS2R14
SCHEMBL24596284 0.76 IGF1R (0.54) HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A LMNA 293/4885OPRM1 578/4885DHODH 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.